90526-08-2 Usage
Description
2-(3-METHOXY-PHENYL)-N,N-DIMETHYL-ACETAMIDE, with the chemical abstracts service number 90526-08-2, is an organic compound that plays a significant role in the field of organic synthesis. It is characterized by its unique molecular structure, which features a 3-methoxy-phenyl group attached to an N,N-dimethylacetamide moiety. This structure endows it with specific chemical properties that make it valuable for various applications in organic chemistry.
Uses
Used in Organic Synthesis:
2-(3-METHOXY-PHENYL)-N,N-DIMETHYL-ACETAMIDE is used as a synthetic intermediate for the preparation of various organic compounds. Its unique structure allows it to participate in a range of chemical reactions, facilitating the synthesis of complex organic molecules. It is particularly useful in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals, where its reactivity and selectivity can be harnessed to produce desired products with high efficiency and yield.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2-(3-METHOXY-PHENYL)-N,N-DIMETHYL-ACETAMIDE is utilized as a key building block in the development of new drugs. Its ability to form a variety of chemical bonds and its compatibility with other molecular fragments make it an ideal candidate for the creation of novel drug molecules with potential therapeutic applications. Researchers can use this compound to explore new chemical space and design innovative pharmaceutical agents that address unmet medical needs.
Used in Agrochemical Industry:
2-(3-METHOXY-PHENYL)-N,N-DIMETHYL-ACETAMIDE also finds application in the agrochemical industry, where it serves as a precursor for the synthesis of new pesticides, herbicides, and other crop protection agents. Its unique chemical properties enable the development of more effective and environmentally friendly agrochemicals, contributing to sustainable agriculture and food security.
Check Digit Verification of cas no
The CAS Registry Mumber 90526-08-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,0,5,2 and 6 respectively; the second part has 2 digits, 0 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 90526-08:
(7*9)+(6*0)+(5*5)+(4*2)+(3*6)+(2*0)+(1*8)=122
122 % 10 = 2
So 90526-08-2 is a valid CAS Registry Number.
90526-08-2Relevant articles and documents
Pd-Catalyzed Site-Selective p-Hydroxyphenyloxylation of Benzylic α-C(sp3)-H Bonds with 1,4-Benzoquinone
Song, Guangjun,Zheng, Ziwei,Wang, Yanhui,Yu, Xinhong
supporting information, p. 6002 - 6005 (2016/12/09)
A Pd-catalyzed, site-selective p-hydroxyphenyloxylation of benzylic α-C(sp3)-H bonds with 1,4-benzoquinone using thioamide as a directing group is reported. 1,4-Benzoquinone is employed as the p-hydroxyphenyloxy source without extra oxidants. T
2-Phenyl-2-(1-hydroxycycloalkyl)ethylamine derivatives: Synthesis and antidepressant activity
Yardley,Morris Husbands,Stack,Butch,Bicksler,Moyer,Muth,Andree,Fletcher III,James,Sielecki
, p. 2899 - 2905 (2007/10/02)
A series of 2-phenyl-2-(1-hydroxycycloalkyl)ethylamine derivatives was examined for the ability to inhibit both rat brain imipramine receptor binding and the synaptosomal uptake of norepinephrine (NE) and serotonin (5-HT). Neurotransmitter uptake inhibition was highest for a subset of 2-phenyl-2-(1-hydroxycyclohexyl)dimethylethylamines in which the aryl ring has a halogen or methoxy substituent at the 3- and/or 4-positions. Potential antidepressant activity in this subset was assayed in three rodent models - the antagonism of reserpine-induced hypothermia, the antagonism of histamine-induced ACTH release, and the ability to reduce noradrenergic responsiveness in the rat pineal gland. An acute effect seen in the rat pineal gland with several analogues, including 1-[1-(3,4-dichlorophenyl)-2-(dimethylamino)ethyl]cyclohexanol (23) and 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol (4), was taken as a possible correlate of a rapid onset of antidepressant activity. Compound 4 (venlafaxine) is presently undergoing clinical evaluation.
